ALK and non-small cell lung carcinoma: Anaplastic Lymphoma Kinase (ALK) rearranged NSCLC is one such subtype identified in 5% of all patients with pulmonary adenocarcinoma, and usually affects younger, non-smoking patients.15 Recent retrospective studies, including from our group, have shown a 3- to 5-fold higher VTE rate in ALK-positive NSCLC.16-18 This is also the case in ROS1 rearranged NSCLC representing 1%-2% of the NSCLC population.19 Data on ATE incidence in specific molecular subtypes are scarce.